Who Owns Atrys Company?

Who Owns Atrys Health?

Understanding Atrys Health's ownership is key to grasping its strategic direction and influence. The company transitioned to the Main Spanish Stock Market in February 2022, a significant step from its BME Growth market days.

Founded in 2007 and headquartered in Madrid, Atrys Health is a global healthtech innovator focused on precision medicine and advanced diagnostics.

Who owns Atrys Health?

The company now known as Atrys was established in 2007, initially operating under the name Europath Biosciences SL. While comprehensive details about all its founders, their specific backgrounds, and the exact equity distribution at its inception are not extensively publicized, the company's foundational focus was on pioneering predictive and personalized oncology therapies. This involved a strong emphasis on clinical and translational research aimed at advancing cancer diagnosis, prognosis, and treatment strategies.

Founding Year and Initial Focus

Atrys Health began its journey in 2007 as Europath Biosciences SL. Its early mission centered on predictive and personalized oncology, driving innovation in cancer care.

Early Capital Infusion

The company secured significant early funding, raising €35 million. This capital came from a diverse group of Spanish investors, including Onchena, Inversiones Industriales Serpis, and Inversiones Inmobiliarias Avilés.

Management and Investor Contributions

Beyond external investors, the company's management team also contributed to this crucial initial capital round. This combined investment was vital for the company's early growth and international expansion efforts.

Public Listing and Market Access

A significant milestone was the company's listing on BME Growth in July 2016. This public market entry facilitated subsequent capital increase transactions and enhanced its financial flexibility.

Diversified Financing Strategies

The company also leveraged BME's Fixed Income market, MARF, to broaden its financing avenues. This included the implementation of bond issuance programs, further diversifying its funding sources.

Foundation for Growth

These early financial activities and strategic investments were instrumental in shaping Atrys Health's trajectory. They established a solid foundation for its subsequent expansion and evolution from its initial ownership structure.

The early financial backing and strategic market entries were pivotal in shaping Atrys Health's growth trajectory. The €35 million capital investment from Spanish entities like Onchena, Inversiones Industriales Serpis, and Inversiones Inmobiliarias Avilés, alongside contributions from the management team, provided the necessary resources for its initial development and international reach. The company's listing on BME Growth in July 2016 was a key step, enabling further capital increases and access to broader financial markets, including the use of MARF for bond issuances. These actions collectively laid the groundwork for the company's evolution and expansion from its founding ownership. Understanding these early financial maneuvers is crucial to grasping the Mission, Vision & Core Values of Atrys.

Complete Atrys Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Atrys Health's ownership journey has been shaped by its transition to the Main Spanish Stock Market in February 2022, significantly expanding its investor base and market presence. This strategic move followed a period of substantial growth, with its market capitalization exceeding €600 million.

The ownership structure of Atrys Health reflects a dynamic interplay between individual, institutional, and strategic investors. As of July 10, 2025, individual investors represent the largest bloc with 42% of the shares, underscoring their significant influence. Excelsior Times SL remains the primary shareholder, holding 25% of the outstanding shares, though this is a decrease from its 30.5% stake in January 2022. The company's capital increase in June 2022, which raised €72 million, attracted family offices and international investors, further diversifying its ownership. This capital injection was instrumental in financing strategic acquisitions, such as that of Bienzobas, and saw existing major shareholders like Onchena and Caser Group, along with the management team, increase their stakes. Notably, Juan María Riberas Mera acquired a 5.432% stake for €28 million during this period, highlighting continued confidence and investment in Atrys's future growth trajectory, aligning with its Growth Strategy of Atrys.

Key Atrys Ownership Details

Understanding who owns Atrys is crucial for assessing its strategic direction and stability. The company's ownership has evolved significantly, particularly after its market listing and capital raises.

• Individual investors hold the largest portion of Atrys shares at 42% as of July 2025.
• Excelsior Times SL is the largest single shareholder with 25% ownership.
• A €72 million capital increase in June 2022 attracted new investors and saw existing stakeholders increase their holdings.
• The company's transition to the Main Spanish Stock Market in February 2022 broadened its investor base.
• Key stakeholders include Onchena, S.L., Global Portfolio Investments, S.L., and Caser Group.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors at Atrys Health serves as the ultimate governing body, responsible for protecting shareholder interests and supervising the executive management. As of May 7, 2025, the company has implemented significant changes to its board and executive leadership to enhance governance and diversity.

The company's governance framework prioritizes a clear distinction between executive and non-executive responsibilities, adhering to recommended governance standards. While specific details on the voting structure, such as whether it employs a one-share-one-vote system or dual-class shares, are not provided, the substantial stakes held by major shareholders, including Excelsior Times SL with 25%, indicate their significant influence on voting power. These leadership transitions, including the planned CEO appointment of Marian Isach and Santiago de Torres's move to a non-executive chairman role, are part of a succession plan initiated in March 2024, emphasizing internal talent development and leadership continuity. There is no public information regarding recent proxy fights, activist investor actions, or governance disputes.

Understanding Atrys Ownership and Board Influence

The ownership structure of Atrys is influenced by its major shareholders, who hold significant voting power. The board's composition reflects a strategic approach to leadership and governance.

• Excelsior Times SL holds 25% of the company's shares.
• The board aims for a separation of executive and non-executive roles.
• Leadership changes are part of a planned succession strategy.
• Understanding who owns Atrys is key to grasping its corporate direction.
• For insights into strategic planning, explore the Marketing Strategy of Atrys.

Atrys Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

In recent years, Atrys Health has undergone significant strategic shifts impacting its ownership structure and leadership. A key development is the planned succession and generational handover, with a new CEO set to take the helm in mid-2025, signaling a focus on internal leadership development.

Financially, the company has demonstrated strong performance, with revenue reaching €212.7 million in 2024, a 5.5% increase, and adjusted EBITDA growing by 13.8% to €48.5 million. This growth is supported by strategic acquisitions, including 6 new ventures primarily in Chile and Spain, with the most recent being Cuidarte in January 2023. The company's proactive approach to capital allocation, including a €72 million capital increase in June 2022 to acquire Bienzobas and the sale of its stake in Conversia, aims to optimize its financial health and leverage. These moves reflect a broader industry trend towards consolidation and specialization in areas like precision medicine and advanced diagnostics, aligning with Atrys Health's expansion into new markets such as Mexico and continued growth in Latin America, which saw a 17.8% increase in Q1 2025. While shareholder dilution occurred with a 23.9% increase in shares outstanding over the past year, the company's market capitalization has simultaneously surged, indicating investor confidence in its strategic direction and growth prospects. Understanding the Target Market of Atrys provides further context to these ownership trends.

Leadership Transition

A succession plan is in place, proposing a new CEO and a shift in the current CEO's role. This indicates a focus on long-term leadership stability.

Financial Performance and Strategy

Robust revenue growth and improved EBITDA highlight financial strength. Strategic divestitures and capital increases are optimizing the company's financial structure.

Acquisition and Divestiture Activity

Multiple acquisitions have expanded the company's reach and service offerings. The sale of a compliance business aims to sharpen strategic focus and reduce debt.

Market Position and Growth Drivers

Expansion into new geographies and growth in key sectors like Oncology and Diagnostics are driving performance. Industry trends in precision medicine support the company's strategic direction.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE